Global

The EU may have a new monitoring scheme for Iceland's volatile geology, but it should also heed the volcano that could blow apart its assumptions on drug pricing and reimbursement, says Reflector.

Is sub-Saharan Africa a jewel box of untapped assets for a growth-obsessed big Pharma? Pharm Exec speaks with Steven Adjei, partner of an investment firm focused on opportunities in the region.

Spain's recession-battered pharma sector adapts to a changing market environment and repositions itself for a return to healthy growth through expanding opportunities abroad.

Leaders from industry, government, and the CRO community examine Ireland's future as a magnet for life science investments, and what the nation must do to remain the leading exporter of finished pharmaceutical products.

2014 kicks off a defining period for healthcare in Chile as a new national drug law is implemented, with the hopes of creating a system that makes access to medicines easier and more transparent for patients.

Industry's grand vision for reshaping the life sciences in Europe may ultimately prove to be a lost cause.

This year's class of 15 young executives is deeply of the moment, with wide-ranging therapeutic, business, and operational expertise-all binded by an underlying commitment to the patient.

The Galien Foundation and the French government investment agency UBIFRANCE have partnered to establish UBISTART, a transatlantic payout for the best in start-up innovations. William Looney reports.

As the "Sovaldi Saga" unfolds in the U.S., it's clear the situation will only deteriorate. But north of the border, it's striking how Canadian healthcare entities are managing a similar Sovaldi situation, writes Tom Norton.

Poland's pharma industry, the largest in Central and Eastern Europe, confronts the fallout from the government's controversial 2012 Reimbursement Act.

Cross-sector partnership seeks support for a pan-European system to keep fake drugs out, but obstacles are many.

How big Pharma stalwarts can avoid a corrosive battle of attrition with local competitors and instead obtain the long-term goal of a stable pricing environment.

India must still be included in the list of promising potential markets for global pharma manufacturers, writes Jill E. Sackman and Michael Kuchenreuther.

Rare allies-innovator and generic pharmas-are calling for policy integration in Europe. But ideology and newfound scepticism on the merits of drugs in healthcare could complicate the effort.

John Ansell assesses the wide range of pharma MBA courses currently available, from the five-day "mini MBA" to year-long programs of study.

Because of the tougher conditions they face and shifts in ownership and corporate strategy, EFPIA and EGA have started to work together much more closely.

India must still be included in the list of promising potential markets for global pharmaceutical manufacturers, write Jill E. Sackman and Michael Kuchenreuther.

MNCs can learn a lot from generic companies in their strategic approaches to emerging markets.

Driven by a rising GDP and calmer political and financial waters over the past decade, Africa's nascent healthcare sector is poised for a fresh surge in growth.

Politicians and health campaigners are celebrating the final agreement of the EU's new clinical trials rules. But the European drug industry is not so euphoric, writes Reflector.

Three strategic implications for pharma pricing strategies in India.

The plan to accelerate generic pricing and reimbursement has become another tragic European casualty.

The possibility of a future "Brexit" - a British exit from the EU - has been exercising the world of medicines, writes Peter O'Donnell.

Brazil is the first Latin American country to emerge as a global biopharmaceutical collaborator. Hellen Berger reports.

UDG Healthcare Integrates Sales, Marketing and Medical Services Offerings